Aura Biosciences Receives FDA SPA Agreement for CoMpass Phase 3 Trial of Bel-sar in Choroidal Melanoma

Aura Biosciences, Inc.

FDA agreed under Special Protocol Assessment to design and planned analysis of CoMpass Phase 3 trial for bel-sar in early-stage choroidal melanoma.
Phase 2 data with 90% follow-up at 12 months showed 80% tumor control and 90% visual acuity preservation in patients meeting Phase 3 criteria.
Preliminary Phase 1 bladder cancer data: first patient with light activation achieved clinical complete response with extensive necrosis and immune activation.
Company terminated ATM equity offering program with Jefferies, suspending sales under existing prospectus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.